Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent

Summary

Statins reduce cardiovascular disease risk and affect endothelial function by cholesterol-dependent and independent mechanisms. Recently, circulating (detached) endothelial cells and endothelial microparticles (EMP) have been associated with endothelial functioning in vitro and in vivo.We investigated whether simvastatin affects endothelial detachment and release of EMP. Human umbilical vein endothelial cells (HUVECs) were incubated with clinically relevant concentrations of simvastatin (1.0 and 5.0 µM), with or without mevalonic acid (100 µM) or gera-nylgeranylpyrophosphate (GGPP; 20 µM) for 24 hours, and analyzed by flowcytometry andWe stern blot. Simvastatin at 1.0 and 5.0 µM increased cell detachment from 12.5 ± 4.1% to 26.0 ± 7.6% (p=0.013) and 28.9 ± 2.2% (p=0.002) as well as EMP release (p=0.098 and p=0.041, respectively).The majority of detached cells was apoptotic, although the fraction of detached cells that showed signs of apoptosis (>70%) was unaffected by simvastatin. Detached cells and EMP contained caspase 3 and caspase 8,but not caspase 9. Restoring either cholesterol biosynthesis and prenylation (mevalonate) or prenylation alone (GGPP) reversed all simvastatin-induced effects on cell detachment and EMP release. Adherent cells showed no signs of simvastatin-induced apoptosis. Simvastatin promotes detachment and EMP release by inhibiting prenylation, presumably via a caspase 8-dependent mechanism. We hypothesize that by facilitating detachment and EMP release, statins improve the overall condition of the remaining vascular endothelium.

Keywords

Anoikis - apoptosis - cardiovascular disease - endothelium - micro-particles - statins

• References

• 1 Collins R, Armitage J, Parish S. et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
• 2 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
• 3 Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Intern Med. 2005 143. 593-599.
• 4 LaRosa JC, Grundy SM, Waters DD. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
• 5 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
• 6 Downs JR, Clearfield M, Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AF-CAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615-1622.
• 7 Baigent C, Keech A, Kearney PM. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
• 8 Colhoun HM, Betteridge DJ, Durrington PN. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
• 9 Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140: 650-658.
• 10 Ferrara DE, Pierangeli SS. Diverse effects of statins on endothelial cells?. Thromb Haemost 2005; 93: 186-188.
• 11 Feng C, Ye C, Liu X. et al. Beta4 integrin is involved in statin-induced endothelial cell death. Biochem Biophys Res Commun 2004; 323: 858-864.
• 12 Tramontano AF, O'Leary J, Black AD. et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004; 320: 34-38.
• 13 Dimitrova Y, Dunoyer-Geindre S, Reber G. et al. Effects of statins on adhesion molecule expression in endothelial cells. J Thromb Haemost 2003; 01: 2290-2299.
• 14 Kaneta S, Satoh K, Kano S. et al. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003; 170: 237-243.
• 15 Kozai T, Eto M, Yang Z. et al. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. Cardiovasc Res 2005; 68: 475-482.
• 16 Eto M, Kozai T, Cosentino F. et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-1759.
• 17 Weis M, Heeschen C, Glassford AJ. et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745.
• 18 Landmesser U, Bahlmann F, Mueller M. et al. Sim-vastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-2363.
• 19 Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208.
• 20 Abid Hussein MN, Nieuwland R, Hau CM. et al. Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost 2005; 03: 888-896.
• 21 Abid Hussein MN, Boing AN, Sturk A. et al. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007; 98: 1096-1107.
• 22 Backman JT, Kyrklund C, Kivisto KT. et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-129.
• 23 Sugimoto K, Ohmori M, Tsuruoka S. et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518-524.
• 24 Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 2004; 320: 165-169.
• 25 Rudel T, Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 1997; 276: 1571-1574.
• 26 Sebbagh M, Renvoize C, Hamelin J. et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 2001; 03: 346-352.
• 27 Li X, Liu L, Tupper JC. et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002; 277: 15309-15316.
• 28 De Staercke C, Phillips DJ, Hooper WC. Differential responses of human umbilical and coronary artery endothelial cells to apoptosis. Endothelium 2003; 10: 71-78.
• 29 Bombeli T, Karsan A, Tait JF. et al. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-2442.
• 30 Hebert MJ, Gullans SR, Mackenzie HS. et al. Apoptosis of endothelial cells is associated with paracrine induction of adhesion molecules: evidence for an interleukin-1beta-dependent paracrine loop. Am J Pathol 1998; 152: 523-532.
• 31 Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-1235.
• 32 Freyssinet JM. Cellular microparticles: what are they bad or good for?. J Thromb Haemost 2003; 01: 1655-1662.
• 33 Hamilton KK, Hattori R, Esmon CT. et al. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-3814.
• 34 Safaei R, Larson BJ, Cheng TC. et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drugresistant human ovarian carcinoma cells. Mol Cancer Ther 2005; 04: 1595-1604.
• 35 Shedden K, Xie XT, Chandaroy P. et al. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res 2003; 63: 4331-4337.
• 36 Mallat Z, Benamer H, Hugel B. et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
• 37 Zeiger F, Stephan S, Hoheisel G. et al. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 2000; 11: 723-728.
• 38 Berckmans RJ, Nieuwland R, Boing AN. et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646.
• 39 Berckmans RJ, Nieuwland R, Kraan MC. et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther 2005; 07: R536-R544.
• 40 Del Conde I, Shrimpton CN, Thiagarajan P. et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
• 41 Joop K, Berckmans RJ, Nieuwland R. et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85: 810-820.
• 42 Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161: 4382-4387.
• 43 Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999; 274: 23111-23118.
• 44 Tans G, Rosing J, Thomassen MC. et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-2648.
• 45 Esposito K, Ciotola M, Schisano B. et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab 2006; 91: 3676-3679.
• 46 Tushuizen ME, Nieuwland R, Rustemeijer C. et al. Elevated endothelial microparticles following consecutive meals are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2007; 30: 728-730.